Share This Page
Patent: 9,834,605
✉ Email this page to a colleague
Summary for Patent: 9,834,605
Title: | Antibodies to human programmed death receptor PD-1 |
Abstract: | Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed. |
Inventor(s): | Carven Gregory John, Van Eenenneem Hans, Dulos Gradus Johannes |
Assignee: | Merck Sharpe & Dohme B.V. |
Application Number: | US14576448 |
Patent Claims: | see list of patent claims |
Patent landscape, scope, and claims summary: | Analyzing the Claims and Patent Landscape of United States Patent 9,834,605 IntroductionUnderstanding the intricacies of a patent, particularly one like United States Patent 9,834,605, involves a thorough analysis of its claims and the broader patent landscape. This analysis is crucial for inventors, patent attorneys, and business strategists to navigate the complex world of intellectual property. Understanding the PatentUnited States Patent 9,834,605 is a utility patent that was granted on December 5, 2017. To analyze this patent, one must first understand its claims, which are the legal definitions of the invention. Claims Analysis
Patent Landscape AnalysisA comprehensive patent landscape analysis is essential to understand the position of the patent within its technological field. Geographical Spread
Saturation of the Patent Space
Time-Slicing and Trends
Competitor Analysis
Subject Matter EligibilityFor patents, especially those involving advanced technologies like AI, subject matter eligibility is a critical issue. The Two-Pronged Framework
Practical Applicability Analysis
Probability of Patent AllowanceUnderstanding the probability of a patent being granted is essential for strategic planning. Overall Allowance Rates
Application Characteristics
Tools and Resources for AnalysisSeveral tools and resources are available to aid in patent analysis. Patent Search Tools
Patent Analytics
Strategic InsightsA thorough patent landscape analysis can provide strategic insights that are crucial for business and R&D decisions. Identifying Niche Areas
Long-Term Decisions
Key Takeaways
FAQsQ: What is the significance of the two-pronged framework in patent subject matter eligibility? A: The two-pronged framework under 35 U.S.C. § 101 helps determine if a patent claim is eligible by checking if it recites abstract ideas (Prong One) and if it provides a specific technological advancement or solution (Prong Two)[2]. Q: How does the geographical spread of patents impact business decisions? A: Understanding the geographical spread of patents helps companies identify key markets and potential competitors, guiding decisions on where to file patents and allocate resources[3]. Q: What is the role of patent analytics in improving patent quality? A: Patent analytics tools automate the review process, catch critical issues, and provide feedback to produce high-quality patent drafts, reducing the risk of costly mistakes and delays[5]. Q: How do continuation procedures affect the probability of patent allowance? A: Continuation procedures can increase the overall allowance rate of patent applications, but the base allowance rate without continuations is significantly lower, around 55.8% for utility patents[1]. Q: What are the benefits of conducting a comprehensive patent landscape analysis? A: A comprehensive patent landscape analysis helps in identifying opportunities, competitors, and trends, enabling companies to make informed strategic decisions about their IP and R&D investments[3]. Sources
More… ↓ |
Details for Patent 9,834,605
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Llc | KEYTRUDA | pembrolizumab | For Injection | 125514 | September 04, 2014 | ⤷ Try for Free | 2034-12-19 |
Merck Sharp & Dohme Llc | KEYTRUDA | pembrolizumab | Injection | 125514 | January 15, 2015 | ⤷ Try for Free | 2034-12-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |